In addition, among the IGHD3 genes, the most expressed was IGHD3-22, which was highly expressed in both COVID-19 patients that underwent ECMO (22.94% COVID ECMO D; 17.51% COVID ECMO S), compared to COVID R (15.45%) and the healthy control (13.60%). This evidence concerns the gene BTK and COVID-19.